Evidence map›Paper›PMID 40621913›Full record

ArticleMicrobiology spectrum2025

Real-world effectiveness and safety of prolonged bedaquiline course in the treatment of drug-resistant tuberculosis-a multi-center retrospective cohort study in a country with a high burden of drug-resistant tuberculosis.

Yuanyuan Yu, Jie Cao, Hongqiu Pan, Hui Zhong, Xiaocui Wu, Jinghui Yang, Liping Cheng, Qingrong Qu, Lei Wang, Fuhui Lu and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yuanyuan Yu *Shanghai Clinical Research Center for Infectious Disease (Tuberculosis), Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.ORCID 0000-0001-7354-0524
Jie Cao *Shanghai Clinical Research Center for Infectious Disease (Tuberculosis), Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Hongqiu Pan *Department of Tuberculosis, The Third People's Hospital of Zhenjiang affiliated to Jiangsu University, Zhenjiang, China.
Hui ZhongDepartment of Infectious Diseases, Shanghai Fengxian Guhua Hospital, Shanghai, China.
Xiaocui WuDepartment of Clinical Laboratory, Shanghai Pulmonary Hospital affiliated to Tongji University, Shanghai, China.
Jinghui YangDepartment of Clinical Laboratory, Shanghai Pulmonary Hospital affiliated to Tongji University, Shanghai, China.
Liping ChengShanghai Clinical Research Center for Infectious Disease (Tuberculosis), Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Qingrong QuShanghai Clinical Research Center for Infectious Disease (Tuberculosis), Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Lei WangShanghai Clinical Research Center for Infectious Disease (Tuberculosis), Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.
Fuhui LuDepartment of Tuberculosis, The Third People's Hospital of Zhenjiang affiliated to Jiangsu University, Zhenjiang, China.
Hongyu ChenDepartment of Tuberculosis, The Third People's Hospital of Zhenjiang affiliated to Jiangsu University, Zhenjiang, China.
Jie WangDepartment of Infectious Diseases, Shanghai Fengxian Guhua Hospital, Shanghai, China.
Wei ShaShanghai Clinical Research Center for Infectious Disease (Tuberculosis), Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.ORCID 0000-0002-2099-8205
Qin SunShanghai Clinical Research Center for Infectious Disease (Tuberculosis), Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, China.ORCID 0000-0003-3445-920X

Funding

Graded diagnosis, treatment and comprehensive management of tuberculosis in Zhenjiang 2021ZD03Shanghai Municipal Health Commission Youth Research Project 20214Y0261Shanghai Scientific and Technological Innovation Project 22Y11900700Three-Year (2023-2025) Action Plan for the Construction of the Shanghai Public Health System GWVI-11.2-XD02
6 · The paper itself

Abstract

Bedaquiline (BDQ) has gradually become a core drug in drug-resistant tuberculosis (DR-TB) treatment, and the additional benefits of prolonging BDQ use remain unclear. Patients with DR-TB who received a BDQ-containing regimen from three Chinese clinical centers between 1 March 2018 and 31 December 2021 were retrospectively analyzed. Treatment outcomes and adverse drug reactions were compared between 6-month and prolonged BDQ treatment group before and after adjustment by propensity score matching (PSM). A total of 160 patients were enrolled, 72 patients were treated with BDQ for 6 months, and 88 patients were over 6 months, of which the median duration was 9 months (IQR: 8-11 months). After PSM adjustment, there were no significant differences in treatment outcome between the prolonged groups (7-9, 10-12, >12 months) and the 6-month group (all

Indexed as

Antitubercular AgentsDiarylquinolinesTuberculosis, Multidrug-ResistantAdultAgedChinaFemaleHumansMaleMiddle AgedMycobacterium tuberculosisRetrospective StudiesTreatment OutcomeAntitubercular AgentsbedaquilineDiarylquinolinesbedaquilineeffectivenessprolongedpropensity score match (PSM)safety

Identifiers

PMID40621913
PMCPMC12323657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.